Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, sodium‐glucose transporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonist (MRA) and glucagon‐like peptide 1 (GLP1) receptor agonists are current therapies for DKD management; however, there remained considerable residual risk of progression to renal failure in DKD patients,3, 4, 5, 6 indicating an unmet need in targeting pathological events in DKD. The gene discussed is NR3C2; the disease is diabetic kidney disease.